Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00200902 · ClinicalTrials.gov registry record · Phase 4
Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression
A Phase 4 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 4
- Development phase
- 88
- Enrollment target
NCT00200902: Completed Phase 4 study, sponsored by University of California, Los Angeles.
NCT00200902 is a Phase 4 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 88 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00200902, a Phase 4 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 88 participants
- Enrollment target
Study Summary
This study will use measurements of depression symptoms and brain activity to determine what factors may influence an individual's response to treatment for depression.
Primary Outcome
Comparison of treatment arms (Medication + ICI, Placebo+ICI, and ICI only). The Hamilton Depression Rating Scale (HAM-D-17) used here is a 17-item scale that measures severity of depression. Items are individually scored from 0-4 or from 0-2 depending on the item, and the individual scores for each item are added to comprise one score. Higher scores indicate greater severity of depression. Possible scores on the scale range from a minimum of zero (0) to a maximum of 52.Response is defined as a 5
Interventions
- OTHER Placebo
- DRUG Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro)
- BEHAVIORAL Interpersonal Clinical Interaction (ICI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2005-08 |
| Est. Completion | 2009-06 |
| Phase | Phase 4 |
What the finished NCT00200902 record still lists
NCT00200902 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00200902 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00200902 about?
NCT00200902 is a clinical study titled "Evaluation of Depression Symptoms and Brain Activity Associated With Response to Treatment of Depression". This study will use measurements of depression symptoms and brain activity to determine what factors may influence an individual's response to treatment for depression.
What is the current status of trial NCT00200902?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 88 participants. The study started on 2005-08. Estimated completion is 2009-06.
What interventions are being tested in trial NCT00200902?
The interventions under investigation include: Placebo (OTHER), Venlafaxine (Effexor), Duloxetine (Cymbalta), Escitalopram (Lexapro) (DRUG), Interpersonal Clinical Interaction (ICI) (BEHAVIORAL).
Who is sponsoring clinical trial NCT00200902?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00200902's enrollment target sits among peer trials
88 916th of 2000 higher than 1,078 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia